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Background: Stigma is a barrier to HIV prevention and treatment. There is a limited understanding of the types of
stigma facing people living with HIV (PLHIV) on antiretroviral therapy (ART). We describe the stigma trajectories of
PLHIV over a 5-year period from the time they started ART.
Methods: Longitudinal qualitative in-depth interviews were conducted with 41 members of The AIDS Support
Organisation (TASO) from 2005 to 2008 in Jinja, Uganda, who were part of a pragmatic cluster-randomised trial
comparing two different modes of ART delivery (facility and home). Participants were stratified by gender, ART
delivery arm and HIV stage (early or advanced) and interviewed at enrolment on to ART and then after 3, 6, 18 and
30 months. Interviews focused on stigma and ART experiences. In 2011, follow-up interviews were conducted with
24 of the participants who could be traced. Transcribed texts were translated, coded and analyzed thematically.
Results: Stigma was reported to be very high prior to starting ART, explained by visible signs of long-term illnesses
and experiences of discrimination and abuse. Early coping strategies included: withdrawal from public life, leaving
work due to ill health and moving in with relatives. Starting ART led to a steady decline in stigma and allowed the
participants to take control of their illness and manage their social lives. Better health led to resumption of work
and having sex but led to reduced disclosure to employers, colleagues and new sexual partners. Some participants
mentioned sero-sorting in order to avoid questions around HIV sero-status. A rise in stigma levels during the 18
and 30 month interviews may be correlated with decreased disclosure. By 2011, ART-related stigma was even more
pronounced particularly among those who had started new sexual relationships, gained employment and those
who had bodily signs from ART side-effects.
Conclusion: This study has shown that while ART comes with health benefits which help individuals to get rid of
previously stigmatising visible signs, an increase in stigma may be noticed after about five years on ART, leading to
reduced disclosure. ART adherence counselling should reflect changing causes and manifestations of stigma over time.
Keywords: Stigma, Antiretroviral therapy, Disclosure, Uganda, Side effects, Sero-sortingBackground
Stigma is a major barrier in the prevention and treatment
of HIV [1,2]. Stigma associated with HIV and AIDS is a
complex concept that has been described as the ‘third
epidemic’ [3]. Goffman (1963) defined stigma as “an
attribute that is deeply discrediting,” and that reduces
the bearer “from a whole and usual person to a tainted,
discounted one”. It refers to “bodily signs designed to* Correspondence: martin.mbonye@mrcuganda.org
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reproduction in any medium, provided the orexpose something unusual and bad about the moral status
of the signifier” [4]. UNAIDS defines both stigma and
discrimination as a “process of devaluation” of people
either living with or associated with HIV and AIDS.
Discrimination is associated with stigma and refers to
the unfair and unjust treatment of an individual based
on his or her real or perceived HIV status [5-7]. While
Castro and Farmer [8] argue that better access to treatment
has the potential to eliminate stigma, there are still
concerns that even with the roll out of antiretroviral
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pointing to the persistence of stigma [9,10].
HIV infection has historically been associated with
immorality and despite advances in knowledge about HIV
and treatment options, the culture of blame remains
relatively strong in many Sub-Sahara African settings
[11]. The fear that surrounds being infected comes from
the realization that one may be found out and judged if
others know their HIV-status [12,13]. A South African
study on stigma experiences of people on ART, concluded
that the body of a person living with HIV is a highly
stigmatized one and this places a heavy burden on PLHIV
[14]. Another study described the stigma trajectories
that PLHIV go through at different stages after the
confirmation of their status, with the need to conceal
being a key strategy especially during the asymptomatic
phase [15]. In order to manage the concealment, with-
drawal from social activities is a favoured approach [16].
Withdrawing from social activities as a strategy against felt
and enacted stigma has already been documented in a
Ugandan population [17-19].
Social stigma contributes to the low uptake of prevention
and treatment services for HIV/AIDS in many African
settings; this is closely linked to reluctance to disclose
HIV sero-status for fear of being labelled or blamed [20].
Yet the disclosure of HIV status is commonly encouraged
as part of positive living and to prevent the further trans-
mission of HIV, with some studies reporting benefits from
public disclosure [21]. While ART allows people to live
a ‘normal’ life, the approach to sexual relationships
tends to become difficult to negotiate within a context of a
community that is aware of one’s status. One strategy that
is increasing in popularity among PLHIV is sero-sorting
where HIV-positive partners get together to avoid the blame
and guilt associated with possibly infecting someone else
[22-24]. However, some have argued that sero-sorting
needs to be approached with caution since it may not
be that effective especially among those who have not
confirmed HIV status [25].
With the wide scale ART roll out and better manage-
ment of HIV in much of Sub-Saharan Africa, the fear of
developing AIDS has now decreased [20]. However, there
are continued challenges of the low uptake of voluntary
counselling and testing and the late presentation of
men, for example, for treatment, which may point to
an underlying epidemic of stigma which continues to
persist [26-28].
In this paper we report on the stigma experiences of a
sample of adults attending The AIDS Support Organisation
(TASO) Jinja branch clinic after confirmation of HIV
infection through to starting and staying on ART for a
period of about three years (2005–2008). We also report
on the experiences of the participants who were followed
up three years later in 2011.Methods
This was a longitudinal qualitative follow up study
with participants drawn from members of TASO in Jinja
district, Eastern Uganda. TASO has over 11 centres
located throughout Uganda that offer counselling, medical
care and other social services to over 90,000 HIV infected
persons and household members [29]. This study was part
of a trial which is described briefly below.
The Jinja trial
We conducted a nested qualitative study in a cluster-
randomized trial which compared ART delivery at home
to that of clients receiving drugs from the TASO Jinja
centre. The trial has been described previously [30]. In
brief, 44 geographical areas in nine strata, defined
according to the ratio of urban and rural participants
plus distance from the clinic, were randomised to the
home-based delivery arm, using trained lay workers or
standard facility-based care by drawing sealed cards
from a box. The trial was integrated into normal service
delivery. In accordance with guidelines at the time, all
patients with WHO stage IV or late stage III disease or
CD4-cell counts fewer than 200 cells per μL who started
antiretroviral therapy between February 15, 2005, and
December 19, 2006, were eligible. Follow-up continued
until January 31, 2009. The primary endpoint was viro-
logical failure, defined as HIV plasma RNA more than 500
copies per mL after 6 months of treatment. The trial
showed that the home-based HIV-care strategy was
approximately equivalent to a standard clinic-based strategy,
and therefore could enable improved and equitable access
to HIV treatment, especially in areas with poor infrastruc-
ture and access to clinic care [30].
The social science longitudinal qualitative sub
study (2005–2008)
The qualitative study was conducted within a radius of
40 kilometres instead of the 75 kilometre catchment area
of the TASO Jinja clinic. This was deliberately done to
manage transport costs during the follow up period. The
main economic activity of the clients that TASO serves
in this area is small-scale farming. There is widespread
poverty in Jinja district [17].
Qualitative sample selection
We selected 41 participants from the main trial (N = 1453).
We planned to recruit equal numbers of men and women
but the death of one male participant during the enrolment
phase, led to his being replaced and so instead of 40 people
we recruited 41. Participants were further stratified by
delivery arm, with the home delivery arm having 21
participants while the facility delivery arm had 20 partici-
pants. Further stratification was based on immunological
or clinical stage, with those who had a CD4 count of
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compared to those who had a starting CD4 of 100 or
below and or with WHO stage 3 or 4. This was done to
compare adherence levels in the first few months on ART
between the two groups. Within each group, participants
were selected consecutively. Data collection was done
at different time periods to capture changes on ART
over time. In the preparatory stages, we conducted two
focus group discussions with ART clients and providers
which formed the basis of the in-depth interview topic
guides. These were pre-tested by experienced and trained
interviewers.
The longitudinal in-depth interviews
The first in-depth interview, which was conducted at the
TASO clinic in 2005, was the enrolment interview and
the main purpose of this interview was to capture expec-
tations and hopes about ART while also exploring illness
experiences in the past. We also used this interview to
build rapport. At this interview, participants were asked
for permission to visit them in their homes for subsequent
interviews which they all consented to. These interviews
were conducted in a private room within the social
science offices located in a separate building from the
TASO clinic. This helped create a free environment for
participants to express themselves.
We then conducted interviews as well as home obser-
vations at 3, 6, 18 and 30 months on ART. At enrolment
we interviewed 41 participants (21 male and 20 female).
At month three we managed to conduct 30 interviews.
Of these, 16 were men because four men could not be
accessed at the time, while one had died earlier. The other
14 were women, five women could not be reached and one
had died. During these interviews we sought to capture
the home context, noting the facilitators and barriers to
adherence as well as the early experience of participants.
We also looked at new developments and how these were
affecting stigma. At month 6 we conducted 34 interviews
of which 20 were with men (one man had died) and 14
were with women. By this time two further women
had died and three others could not be reached. These
interviews followed the same themes as the ones conducted
at month three. At 18 months we interviewed 18 men
(three had died by then) and 17 women (three had died by
then). At this time we focused on longer term experiences
with ART and any experiences of stigma now that many
had resumed public life, including returning to work. For
those who had started new sexual relationships, we asked
about factors influencing partner choice, disclosure and
reproductive health issues. At 30 months we interviewed
33 participants of which 17 were men (three had died and
one refused) while the women were 16 (four had died).
These interviews covered long term experiences with ART
and stigma, as well as summarising experience over thestudy period. We also paid attention to the emerging
narratives of changing patterns in stigma. At the end of
these interviews, we asked the participants to assess
themselves using percentages about how they felt stigma
may have changed over the two and a half year period
since starting ART.
Home observations were guided by a checklist which
included important cues such as: neighbourhood envir-
onment, medicine storage, interaction of participant with
external environment, household support structure and
information that could facilitate understanding of barriers
or enablers for adherence. One male and two female inter-
viewers, recruited participants at enrolment and each
interviewer stayed with the same participants throughout
the study to ensure continuity and allow for building and
strengthening of the rapport with the participants.
Interviews were tape recorded with permission and
predominantly conducted in Luganda language with only
two participants interviewed in English. These interviews
were transcribed and translated later with care being
taken to use identifiers rather than names to maintain
confidentiality. We developed an identifying system whereby
the first letter represented gender (Male - M or Female - F),
the next letter represented the ART delivery arm (F-for
facility and H for Home delivery), and the third letter
represented the clinical/Immunological stage (L for low
CD4 count below 100 and H for high CD4 over 150). The
final digit was a number which represented one up to five
participants in a particular stratum. In one stratum this
number reached six because of the participant recruited
to replace the participant who passed away during the
enrolment phase. The quotations used in the manuscript
will adopt these codes as identifiers. Interviews lasted for
about one hour although the 30 month interviews were
slightly longer.Focus group discussions (FGDs) with TASO staff
(after 30-month interviews)
We also conducted two focus group discussions, one
with TASO staff engaged in service delivery at the clinic
(this comprised of trained counsellors) and another with
the lay field officers who took drugs to participants in their
homes. The focus group discussion with facility based
professional counsellors was conducted at the TASO
Jinja offices in a private location and it included 13 partici-
pants, four of whom were men while the rest were
women, reflecting the gender distribution of the staffing
in the counselling department. On the other hand, the
group discussion with lay workers who delivered drugs to
the homes of TASO clients comprised of 12 men and one
woman. This also reflected the ratio of men to women in
this department. Both interviews lasted for about one hour
and a half. These were conducted after the 30 months
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and the role of the provider in facilitating it.
Longer term follow up interviews (2011)
We did a further follow-up of this social science cohort
in 2011 to capture more recent trends. Informal semi-
structured in-depth interviews using an interview guide
were conducted with 24 of the 34 participants who we
were able to re-contact. Key themes explored included:
participants’ experience with ART adherence over the
years, perceptions about stigma, changes in lives and
livelihoods and how this fitted into their routine. These
interviews were conducted at the homes of the participants.
Some participants had shifted to places which were distant
and this meant we could not reach them, while others
had died in the period between 2008 and this follow up.
The relatives of those who had died explained what they
thought the cause of death had been (fever, alcohol,
unknown causes, for example). By 2011 seven of the 41
participants had died.
Data analysis
Thematic coding was aided by the use of NVivo 8 software.
Analysis focused on how stigma was being encountered
at both personal and community levels. We used a
chronological approach to map out the changes in stigma
over time noting how the different time points after
initiation of ART represented new opportunities and
challenges. Two junior social scientists and one senior
social scientist participated in the initial stages of develop-
ing the code book. This team read the same five scripts
from each interview round and identified themes that
related to stigma or experiences which might depict
stigma. A group meeting was then held which looked
at themes from both the topic guide and any that might
have emerged inductively. In case of disagreement, a team
meeting was held and a consensus reached. This process
continued until a code book that captured stigma trajec-
tories over the two studies was obtained.
A master NVivo 8 project was then developed and this
was controlled by one of the senior social scientists. The
analysis team (which also included two senior social
scientists) started the coding process with weekly meetings
being held to ensure inter coder reliability. At the end of
the process, the three different projects were merged into
the master copy. We plotted individual experiences based
on what the interviewers observed over time and the
narratives of the participants in order to gain a nuanced
understanding of their experiences with stigma and ART.
The final themes are presented in the results and illustra-
tive quotations are provided from different time points to
show changing patterns. Thematic analysis, using themes
drawn from the 2005–2008 study, was also used for the
analysis of the 2011 data.The study was approved by the Uganda Virus Research
Institute Science and Ethics Committee, the Uganda
National Council for Science and Technology as well as the
ethics boards of the US Centers for Disease Control and
Prevention, and London School of Hygiene and Tropical
Medicine. Written informed consent was given before all
the interviews while verbal consent was secured for the
focus group discussions. Participants were offered a snack
and a soft drink at enrolment since interviews were held
at the clinic. In subsequent interviews at home (3, 6, and
18 months and in 2011) we offered them a bar of laundry
soap. For the 30-month interview we gave a large plastic
washing basin as a token of appreciation.
Results
Sample characteristics
The age range of the participants at enrolment was
between 22 and 62 years with a median age of 35 for
women and 40 years for men. A number of participants
who did not have a sexual partner at enrolment reported
having secured one in later months and also during recent
follow up interviews in 2011. Many of the women reported
being widowed at enrolment although some of these had
initiated new partnerships by the thirtieth month. Most
were Christians (Catholics, Anglicans and Pentecostals)
with only four Muslims. Participants were from very
poor social economic backgrounds and depended on close
family and friends for a living especially in the first year on
ART. However, within the first year of initiating treatment
many resumed work and became independent once they
had regained their strength. Throughout the course of the
research, most people performed low skilled work like
small-scale farming around homes and offering similar
services for a fee in the neighbourhood, selling retail goods
near homes or working in nearby fishing villages. A few
remained jobless and dependent on support systems, while
others said they had become housewives after securing
supportive new sexual partners. Below is a vignette that
looks at the stigma experience of one participant:
Stigma trajectory of a female participant
FFL3 was a Muslim woman of 30 years who had four
children by the time of the enrolment interview. She had
separated from her partner. She first suspected possible
HIV infection when she was told by a friend who had
met her former partner and reported that the partner
had lost a lot of weight and looked very frail. Her suspi-
cions grew stronger when she saw the former partner’s
condition and she also started developing illnesses which
worsened rapidly, until she had to be admitted to hos-
pital. It was then that she discovered that she too was
infected with HIV. Her reaction to this was fear that she
was going to die and leave her children without anyone
to take care of them. She also felt shame and guilt for
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withdraw from the public eye for fear of being blamed
for having HIV. After a few months on ART she noticed
a dramatic improvement in her health and regained her
former weight. She was back to her former beauty, by
her own admission, and was no longer afraid of mixing
with other people. She opened up a retail shop and a
vegetable shop near her residence. This allowed her to
continue taking her drugs on time and she was really
happy with how things were going. With time she started
reconsidering her stance of never resuming sexual rela-
tionships but was worried about the reaction of those in
her community who had known about her illness. She
eventually met a man who was a night watchman but who
resided far away from her village. She did not tell him
about her status and the fact that she was on ART. He
also never asked about her history but wanted to have a
child. Condoms were only used for a short while and soon
she noticed that she was pregnant.
At a later stage we were informed by her medicine
companion that she was not well (the role of a medicine
companion is described elsewhere [31]). Things began
to change. Apparently she was advised by a friend
attending the TASO clinic that she needed to abort as
a pregnancy was not good for someone of her status.
She also feared the possible negative reaction from
people who would see that she was now sexually active.
She attempted an abortion from a fraudulent doctor on
the recommendation of a friend who had successfully
had an abortion from this person. She soon developed
complications leading to her hospitalization and eventual
death.
This story represents a series of occurrences that
impacted on one woman’s life while taking ART. Her
fear of possible negative reactions to resuming sex, which
many shared in this study, led her to look outside her
community for a partner and reproductive demands soon
followed leading to a pregnancy. We see how a very posi-
tive outcome (starting ART and getting rid of stigmatizing
signs) led to a fatal action based on how she interpreted
her options at the time.
Coping with HIV infection
In order to appreciate the changes in the lives of the
participants it is important to look at how they first
encountered the diagnosis as well as their own perception
of HIV/AIDS before they got the infection.
Prior to finding out about her status, participant FFH3
confessed that she could not imagine herself with the
infection. She said:
‘Before I learnt that I was infected, if one told me that
I had HIV/AIDS, we could even quarrel,
“did you infect me, I would ask such a person?”.But eventually she experienced continuous illnesses
which she tried to ignore but their persistence forced her
to confront the possibility of HIV infection. She had earlier
lost a husband to what was then described as cancer, which
in itself was one way of disguising AIDS-related disease in
the community [29]. She said:
I realized that I was sick and was always having fever
and I said that: “mother, could it be that this man
died of HIV/AIDS?” [She continued to narrate about
her late husband] He never told me that he had HIV.
We [meaning her late husband] were even admitted to
Jinja hospital but he told me he was suffering from
cancer.
To protect the reputations of the deceased, the cause
of death was often concealed which raised the levels of
suspicion and fear. A number of participants had moved
in with supportive relatives when they were weak and
unhealthy following prolonged illnesses. This environ-
ment of shame and blame was best managed carefully in
order to minimize the assumed damage to their reputation.
As a result each individual seemed to tap into personal
reserves to cope with real and assumed stigma. At the
30 month-interviews, participants made self-assessments
about how they rated themselves in terms of stigma. Nine
women reported that they felt stigma at levels between 90
and 100% at enrolment. Explaining, FFH3 felt very shy
and ashamed, in her own words she said: I even feared
going to TASO. I used to fear a lot and someone even told
me that they give you drugs to kill you if you went to
TASO. FFH4 was more worried about people finding out
through her daily drug taking: I had much stigma I
wondered what people would say when they saw me
swallowing the tablets. However, she commented: No
one rejected me at all. That was within me, myself.
From such narratives, we see the source of stigma being
multiple and encompassing the infected person, their
immediate and external environment as well as the social
support organisation and yet they had to belong to the
support organisation to manage their progressing disease.
How initiating ART affected stigma
Having initiated ART, the participants, especially the
women, anticipated great changes in their health. Many
had witnessed the positive effects of Cotrimoxazole prophy-
laxis and were anticipating even better changes from
ART, having heard and seen the changes in other TASO
members who were already taking the medication. They
said that they hoped to avoid the side effects that could
potentially reverse the health gains. It seemed from the
perspective of many that the aim was to keep visible body
signs at bay with the hope that initiating ART would help
achieve this. Indeed in the first few months this hope had
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fully satisfied with how their lives had been transformed.
One participant, however, expressed concerns that the
signs of infection were not disappearing as quickly as she
had anticipated:
…The skin was bothering me but now I can see that it
is improving. It will improve, but it seems here
[pointing at part of the skin with a rash] I was bitten
by mosquitoes. I fear people who see me; they may ask
themselves that what is wrong with her?
(FFH4, 30-month interview)
Continuing side effects and stigma
As the longitudinal qualitative study came to an end in
2008, we began hearing about changes in the way people
felt about themselves. Then when we conducted the
follow up interviews in 2011 we observed that for some
participants ART was no longer the magic bullet that
was taking care of stigmatizing signs on their bodies. In
fact these people had started connecting the new forms
of strange bodily signs with ART. This had the potential
to bring back strong feelings of shame. The signs reported
included: loss of facial fat and darkening of the skin. Both
men and women reported these signs but the women
seemed particularly concerned. One participant who was
experiencing these changes presented their feelings in the
following illustration:
They told us that if you take these drugs, you don’t get
other sicknesses but now you see how my eye looks, I
thought that if I take the drugs for a long time all the
sicknesses would go and I remain with only the virus.
(FHL1 in 2011)
The changing stigma trajectories associated with bodily
signs for one participant, MHH3, are illustrated in the
extracts below:
At 3 months he had no problems with home visits by
TASO, having been randomized to receive drugs at home:
…I’m very thankful that I am here in Uganda, in Jinja
and I am even able to receive my drugs from home.
At 6 months on ART, the positive feelings continued:
…there has been a great change because since I started
taking the drugs, I have never fallen seriously sick. I
sometimes even forget I have HIV.
A similar response was reported throughout the rest of
the follow up period up to 30 months on ART, but there
was a marked change in attitude when re-contacted in
2011. The participant had by then experienced side-effectsand was not as happy with the bodily changes he was
experiencing:
You see my mouth has changed its shape and even
my face is pale with sunken eyes. Even though I try to
add some Vaseline on my face it doesn’t change.
People can think that I don’t bathe properly
according to the way my skin looks. As a human
being, I feel bad but there is nothing to do about it.
I don’t mind if one talks about me and I can’t
quarrel with him or her but in my mind it hurts me.
(MHH3 in 2011)Resumption of public life
Not all participants reported poor results from ART and
in fact the majority were very satisfied, and felt that they
had fully reintegrated into society and started interacting
with other people without fear of being isolated. As a
result these people had started to work again, thus gaining
greater independence. However new challenges were
registered for those who were employed or who worked
within a public setting as well as some who had been
randomized to receive drugs from the home based arm.
The labelled vehicles and motorcycles were by 2008,
becoming a source of discomfort to the extent that by the
30-month interview, strategies and arrangements were
being negotiated with drug delivery staff from TASO to
receive drugs in neutral locations. The following quote
about the home delivery of drugs with a TASO labelled
motorcycle illustrates this point:
… Of course that is not a very comfortable situation
(laughs) especially when the motorcycle has something
labelled on it like TASO or something like that.
[but now] the field officer who supplies me usually
does not just ride the bike up to my place, he parks
it somewhere and then he walks to my place that
is if we are to meet at my place, and if not then
he tells me to find him somewhere.
(MHH3, 30-month interview)
Echoing the above trend, TASO staff during the group
discussions reported a change in attitude towards the
visibility of TASO in the participants’ homes. They agreed
that some participants in the home based arm were
increasingly beginning to show discomfort with the
routine drug deliveries yet they had not had any problem
with this earlier on. In other cases, some participants had
taken on new jobs and were not yet ready to disclose to
employers or colleagues at work, yet they had to find time
for ART delivery. The participants in the focus group were
all in agreement regarding this issue. The following quote
captures this perception:
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their health, and they have obtained jobs. When they
see a TASO counsellor or any provider they always
tend to hide. They now do not want to associate with
HIV which shows that there is some kind of increased
stigma. But before joining and gaining weight when
they had all these signs and symptoms, they would
even invite you [to their home]. (Male counsellor in
FGD of facility based staff )
Sexual, reproductive health, disclosure and stigma
Perhaps one of the most important aspects of full recovery
for participants was the aspect of sexual and reproductive
health. There was a strong contrast between the narratives
of, for example, many women who as they had begun
ART had vowed never to resume sex as they struggled
with the various illnesses and sad memories of how they
had become infected. The possible negative reactions from
a suspicious public were also a deterrent particularly given
that many of these people had a very public and visible
illness experience either through the death of a spouse or
because of their own illness. With time on ART however,
by the thirtieth month, seven of these women were in a
relationship, had had a child or were currently pregnant.
The partners they had were rarely aware of their HIV
sero-status and although this worried the women because
of the potential for infecting these partners, such decisions
not to disclose were often rationally made after weighing
up the costs of losing the new relationship. The following
excerpt from the interviews illustrates this point:
Question: Now, you don’t know his status…how do you
feel about the fact that he might contract it [HIV/AIDS]
if he didn’t have it?
FHH3: Well, the problem is I might tell him and it
causes me problems because the ways of men are
complicated. He might beat you and say you infected
him yet he may at times have it too. Because he is a
mature person, it is not me that he first had a
relationship with. (FHH3 30-month interview)
Another woman (FFL2) who had started a relationship
with a man whose status she did not know narrated at
the 30-month interview that she had ended up getting
pregnant shortly after what started as a casual
relationship.
Question: Did you disclose to him your HIV status?
FFL2: No
Question: But do you think he knows?
FFL2: He doesn’t know [her status]
Question: Do you know about his status?
FFL2: I don’t knowQuestion: Do you use a condom?
FFL2: We were using, but he reached a time and he lied
to me that he had put it on but then I came to realize
other things [She got pregnant].
For the women, increasing age seemed to be associated
with avoidance of sexual relationships. Of the eight women
who were over 40 at enrolment, only one reported being
in a relationship during the 2011 interviews, although this
relationship did not involve sexual intimacy because her
husband was HIV-negative. She was accepted by her co-
wives and as we see in her narrative below, she was happy
to maintain her abstinence at age 48 years. She said:
As I have told you that my husband is HIV negative
and even my co-wives are HIV negative, we decided
not to have sex again and ever since I was found
positive, we have never had sex. We have a good
relationship with my co-wives and even my husband.
I no longer think about those issues.
(FHL3, at the 2011 interviews)
In focus group discussions, TASO staff admitted that
there was some shame attached to pregnancies which
could have arisen from previous messages which were
interpreted by clients as discouraging pregnancy. This
finding has been reported in more detail elsewhere [23].
A discussant in the focus group had this to say on this
topic:
…You know what happens is that when they [clients]
come here some especially those ones who are pregnant
have the fear or they feel ashamed. You know it’s a
process. Usually here such a client has to see a
counsellor. So imagine they have been telling a
counsellor for some time that they are abstaining and
now the counsellor sees that they are pregnant, so if
they come here they wonder what they will tell such a
counsellor. (Male, field officer FGD)
Another field officer noted that there was a missed
opportunity for further counselling as participants with
pregnancies stayed away from TASO. The fear of some
staff was that these participants may come to harm because
there are some drugs that the providers were made aware
of that could harm the unborn baby as well as methods
available to reduce the chance of vertical transmission.
The participants in the focus group gave examples of this
scenario:
…even me I have one client on combivir/efavirenz, she
is now seven months pregnant but whenever I refer her
for change of regimen she says that she comes to the
clinic but then she disappears without seeing anyone.
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and sat there since morning up to 6pm and no one
attended to her yet in actual sense her file was
retrieved and taken to the clinician but she was being
called and she was nowhere to be seen. (Male field
officer FGD)
Sero-sorting as a strategy against stigma
Some participants deliberately looked for same HIV-
positive status partners. This was a strategy to avoid
public scrutiny about their sex lives involving people of
unknown status or those thought to be uninfected.
Although no one experienced any enacted stigma as a
result of engaging in a sexual relationship, the reports by
those who sero-sorted seemed to point to the possibility
of this existing within the community. One female partici-
pant observed:
Let me tell you when there is health, there is life. I
tried very much to be single but when I couldn’t hold
on any longer I got someone who was also with TASO
and is on medication. (FFL5, 30-month interview)
It is worth noting that those participants, who had
started new sexual relationships on the basis of sero-
sorting, sometimes depended on the self-report by the
new partner. Among the women who had resumed sex-
ual relationships, only one seemed sure of the status of
the new partner since they had met at TASO. Another
one assumed her partner was HIV positive but never
really confirmed this. She tried to make enquiries about
him and even encouraged him to visit TASO but he
seemed reluctant to do so as seen in the quote below:
…When he talked about starting a relationship with
me I told him about my health status and he also told
me that he was HIV positive and on drugs…I asked
him to go and see my counsellor and he refused saying
that he didn’t have time to go to TASO…I have never
seen him taking them [referring to ART]… He told me
that he takes his drugs at 8am, he goes to work at
exactly 7am in the morning and he comes back home
at around 10.00pm in the evening. He may be taking
them after he has left this home. (FHL2, 30-month
interview)
In some cases a participant either looked for a partner
privately from among others within TASO or used friends
to link them up to others who were of the same status.
The support and wise counsel when it was sought and
obtained from TASO staff tended to help them feel
comfortable with the choice of partner. The pregnancies
that followed new sexual relationships were also easy to
deal with when the participants had informed TASO staff,and in such cases advice such as prevention of mother-
to-child transmission was given and if any drug changes
were necessary, then this was also done. Those who
sought help from staff were more confident about their
situation than those who hid from TASO. A male par-
ticipant who obtained a second partner in such a way
narrates:
… A few years ago I found a lady who was HIV
positive… then TASO office decided to introduce a
community drug distribution point in my
community…Whenever I went there I could find her
also having gone for drugs. I talked to the person
giving out the drugs. He told me that it was okay
[to have a baby] if she was also HIV positive. They
told us not to breast feed the baby and we did not and
already I had some information about PMTCT.
(MFH2, 30-month interview)
Perceptions on possible re-infection and infectiousness
On the issue of re-infection which was a concern at
enrolment and featured heavily in the conversations
regarding the adherence counselling, participants seemed
aware of the risk but were almost powerless to take action,
feeling that having a same status partner was as far as they
could go. The following excerpt from an interview with a
male participant (MFL4) at the 30-month interviews
shows the choices that have to be made by people living
with HIV on ART as a strategy for avoiding stigma related
to resuming sex, as well as the guilt of possibly infecting
others:
Question: To what extent does spreading the virus to
other people worry you?
MFL4: It worries me so much and that’s why I got a
fellow HIV positive partner because I wanted someone
who knew that I have the virus. Now in case I love
another person who is not infected, it is like taking a
panga [large knife] and cutting her. That is real hatred;
it is not good to spread this disease.
Question: Now you have said you don’t use condoms, to
which extent does contracting other diseases from your
partner worry you?
MFL4: We don’t use it but I know that if she has other
diseases she can spread them to me.
The above participant while demonstrating knowledge
about the risk of re-infection in the absence of condoms
even after sero-sorting, was still reluctant to use con-
doms as a means of protection against such risks. This
demonstrated how these participants who seemed very
knowledgeable had to explore several choices although
in some cases the choices were very limited and there
was a potential risk in a particular choice taken.
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In this paper we have presented the stigma experiences
of clients enrolled in an AIDS support organisation from
the time they started taking ART over a 6-year period. It
is widely agreed now that HIV is a chronic condition
which needs to be managed as such and the ammunition
to do this is available [32,33]. Our participants had
access to a comprehensive package that addresses their
psycho-social needs. These people had been deemed to
be ready for treatment [17]. For this population as is the
case for many people living with HIV the source of
stigma were the physical bodily attributes which are
significantly discrediting [4,34]. We also noted that
infection with HIV in a setting like Uganda requires the
affected individual to negotiate various challenges at the
personal and structural level. For example individuals have
to negotiate various identities from the time of infection in
order to fit into the role of an HIV-infected individual [35].
Along the way, individuals may withdraw from activities
that might expose them as being infected with HIV [36].
The start of AIDS related bodily symptoms or the fear of
these happening in future triggers stigmatizing feelings
[12,37]. The inability to conceal symptoms is described as a
source of stigma. We found in our study that people
develop strategies to overcome the anticipated or real
stigma by either withdrawing from public activities as
they seek advanced treatment options to cope [17], avoiding
disclosure even to sex partners after they have recovered
from the debilitating symptoms and resumed their sex lives
[21], and sero-sorting which also helps minimize the burden
of guilt that one could pass on the infection to someone
else [23,38]. However, we also noted that it was not always
straight forward. As has been reported elsewhere, sero-
sorting may not actually be that protective in situations
where the sero-status cannot be established beyond doubt
[39,40]. It is worth also noting that sero-sorting may not
provide protection against superinfection which could com-
plicate ART treatment or even increase incidence [41,42].
Despite the challenges, some of our participants con-
fronted the stigma bravely having embraced their new
illness identity [43]. This latter strategy is the preferred one
for the support organisation these people are attached to.
The roll out of ART led to a reported rapid early
decrease in stigma among this study population, attributed
to the clearing of visible signs in the majority of the cases.
However new dilemmas arise as health improves. The need
to restart or fit into expected societal roles may drive
behaviour [33]. As health improves and people resume
their lives and livelihoods, stigma associated with drug
taking may emerge. Some participants in our study
preferred not to disclose their status arguing that it
served their interests better by keeping this secret. The
reluctance to disclose to new employers/sexual partners
and continue unprotected sex with such partners despitethorough counselling from TASO further illustrates this
dilemma. Resumption of sexual relationships ties in with
the cultural pressure to have children, which is a cherished
goal of many women in countries such as Uganda and
it appears that improvements on ART seems to be
resurrecting this desire [44].
This study presents interesting developments about
the changes in stigma among people living with HIV on
ART over a period of about three years and some insights
into their lives after the close of the 2005–2008 study.
However, it has some limitations which need to be taken
into consideration when interpreting these results. This
study was conducted among TASO clients who receive
good regular counselling and their high rates of adherence
and reduced levels of stigma could be as a result of the
psycho social support they receive. This makes it hard to
generalize these results to populations that do not access
this professional help. The possibility that others may stay
away from TASO could potentially be attributed to stigma.
Nevertheless, the changes in social and livelihood
options that we began to notice towards the end of 30
months and the associated stigma that was unanticipated
and never captured in the psycho social readiness activities
at enrolment seem to cause challenges which may eventu-
ally affect high long term adherence as well as having
implications for prevention and care.
Conclusions
Pre-ART stigma was reportedly high in this population
manifested in withdrawal from social activities to avoid
blame and shame. HIV-related stigma is reported to have
reduced after initiation of ART but as time passed condi-
tions changed, new situations were encountered, and this
may have triggered an increase in the stigma participants
taking ART felt. The illness and dependence on others that
these participants report before starting ART motivated
them to adhere well. The dramatic positive changes that
occurred after initiating ART helped reduce stigma.
However, as lives were rebuilt and the social and economic
contexts began to change, there was a noticeable re-
emergence of stigma which began to take shape as PLHIV
restarted social, economic and emotional roles. This stigma
was related to bodily changes and in some cases being seen
taking ART. They tried to recreate a new identity which
tended to downplay the importance of their HIV infection
for fear of destabilizing their newly acquired identities.
Sero-sorting also gained prominence as a strategy to
manage infection and new relationships. Adherence to
drugs may become challenging, which calls for the devel-
opment of new strategies by support organisations to
deal with this new face of stigma. We recommend that
innovative counselling messages be reinforced periodically
and that an appreciation of the changing patterns of stigma
be reflected in these messages.
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